JAK1-IN-9

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK1-IN-9 

JAK1-IN-9 (compound 23a) 是一种有效的选择性 JAK1 抑制剂,IC50 为 72 nM。JAK1-IN-9 对其他 JAK亚型 具有 12 倍或更多的选择性。

JAK1-IN-9

JAK1-IN-9 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

JAK1-IN-9 (compound 23a) is a potent and selective JAK1 inhibitor with an IC50 of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more[1].

IC50 & Target[1]

JAK1

72 nM (IC50)

JAK2

839 nM (IC50)

分子量

416.22

Formula

C16H13IN6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. WooChan Kim, et al. Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors. Bioorg Med Chem Lett. 2022 Jan 1;55:128451.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK1-IN-9

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK1-IN-9 

JAK1-IN-9 (compound 23a) 是一种有效的选择性 JAK1 抑制剂,IC50 为 72 nM。JAK1-IN-9 对其他 JAK亚型 具有 12 倍或更多的选择性。

JAK1-IN-9

JAK1-IN-9 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

JAK1-IN-9 (compound 23a) is a potent and selective JAK1 inhibitor with an IC50 of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more[1].

IC50 & Target[1]

JAK1

72 nM (IC50)

JAK2

839 nM (IC50)

分子量

416.22

Formula

C16H13IN6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. WooChan Kim, et al. Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors. Bioorg Med Chem Lett. 2022 Jan 1;55:128451.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK1-IN-9

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK1-IN-9 

JAK1-IN-9 (compound 23a) 是一种有效的选择性 JAK1 抑制剂,IC50 为 72 nM。JAK1-IN-9 对其他 JAK亚型 具有 12 倍或更多的选择性。

JAK1-IN-9

JAK1-IN-9 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

JAK1-IN-9 (compound 23a) is a potent and selective JAK1 inhibitor with an IC50 of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more[1].

IC50 & Target[1]

JAK1

72 nM (IC50)

JAK2

839 nM (IC50)

分子量

416.22

Formula

C16H13IN6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. WooChan Kim, et al. Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors. Bioorg Med Chem Lett. 2022 Jan 1;55:128451.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK1-IN-4

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK1-IN-4 

JAK1-IN-4 是一种有效、选择性的 JAK1 抑制剂,对 JAK1,JAK2 和 JAK3 的 IC50 值分别为 85 nM,12.8 μM 和 >30 μM。在 NCI-H 1975 细胞中,JAK1-IN-4 抑制 STAT3 的磷酸化,IC50 值为 227 nM。

JAK1-IN-4

JAK1-IN-4 Chemical Structure

CAS No. : 2091134-35-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

JAK1-IN-4 is a potent and selective JAK1 inhibitor, with IC50s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM)[1].

IC50 & Target[1]

JAK1

85 nM (IC50)

JAK2

12.8 μM (IC50)

分子量

521.59

Formula

C26H32FN9O2

CAS 号

2091134-35-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Annika Birgitta Margareta ÅSTRAND, et al. Compounds and methods for inhibiting jak.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

SJ10542

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

SJ10542 

SJ10542 是一种有效的选择性 JAK2/3 导向苯基戊二酰亚胺 (PG)-PROTAC,对 JAK2、JAK3 和 JAK2-fusion ALL 的 DC50 分别为 14、11 和 24 nM。SJ10542 利用PG 配体作为 cereblon (CRBN) 招募剂。

SJ10542

SJ10542 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

SJ10542 is a potent and selective JAK2/3 directing phenyl glutarimide (PG)-PROTAC with DC50s of 14, 11, and 24 nM for JAK2, JAK3, and JAK2-fusion ALL, respectively. SJ10542 utilizes a PG ligand as the cereblon (CRBN) recruiter[1].

IC50 & Target[1]

JAK2

14 nM (DC50)

JAK3

11 nM (DC50)

Cereblon

 

JAK2-fusion ALL

24 nM (DC50)

分子量

818.95

Formula

C41H46N12O5S

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Lisa J.Alcock,et al. Development of Potent and Selective Janus Kinase 2/3 Directing PG-PROTACs.ACS Med.Chem.Lett.2022,13,3,475-482.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

XL019

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

XL019  纯度: ≥98.0%

XL019 是一种有效的、口服活性的、选择性的 JAK2 抑制剂,对 JAK2,JAK1,JAK3 的 IC50 分别为 2.2、134.3、214.2 nM。XL019 对JAK2的选择性是 100 多种丝氨酸/苏氨酸和酪氨酸激酶(包括 JAK 家族的其他成员)的 50 倍或更高。XL019 对 JAK2 V617F 和野生型 JAK2 细胞中 STAT3 和 STAT5 磷酸化的抑制作用。

XL019

XL019 Chemical Structure

CAS No. : 945755-56-6

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥990 In-stock
5 mg ¥900 In-stock
10 mg ¥1500 In-stock
50 mg ¥4500 In-stock
100 mg ¥7500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

XL019 相关产品

相关化合物库:

  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Orally Active Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Targeted Diversity Library
  • Anti-Liver Cancer Compound Library

生物活性

XL019 is a potent, orally active, and selective JAK2 inhibitor, with IC50s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2[1][2].

IC50 & Target[1]

JAK2

2.2 nM (IC50)

JAK3

214.2 nM (IC50)

体内研究
(In Vivo)

XL019 (100-300 mg/kg; p.o.; twice daily for 14 days) inhibits HEL.92.1.7 xenograft tumor growth[1].
XL019 (10 mg/kg) treatment shows that the Cmax, t1/2 and Vd were 5.24 μM, 1.94 hours, 5.319 L/kg, respectively[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nude mice (HEL.92.1.7 xenograft tumors)[1]
Dosage: 100, 200, 300 mg/kg
Administration: p.o.; twice daily for 14 days
Result: Inhibition of HEL.92.1.7 xenograft tumor growth.
Animal Model: Mouse[1]
Dosage: 10 mg/kg
Administration: p.o.(Pharmacokinetic Analysis)
Result: The Cmax, t1/2 and Vd were 5.24 μM, 1.94 hours, and 5.319 L/kg, respectively.

Clinical Trial

分子量

444.53

Formula

C25H28N6O2

CAS 号

945755-56-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 25 mg/mL (56.24 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2496 mL 11.2478 mL 22.4957 mL
5 mM 0.4499 mL 2.2496 mL 4.4991 mL
10 mM 0.2250 mL 1.1248 mL 2.2496 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.62 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.62 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Forsyth T, et al. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7653-8.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK1-IN-8

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK1-IN-8  纯度: ≥95.0%

JAK1-IN-8,有效的 JAK1 抑制剂 (IC50< 500 nM),化合物 28,从专利 WO2016119700A1 中获得。

JAK1-IN-8

JAK1-IN-8 Chemical Structure

CAS No. : 1973485-18-5

规格 价格 是否有货 数量
5 mg ¥500 In-stock
10 mg ¥900 In-stock
25 mg ¥1800 In-stock
50 mg ¥3200 In-stock
100 mg ¥5400 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

JAK1-IN-8 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Liver Cancer Compound Library

生物活性

JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nm), compound 28, extracted from patent wo2016119700a1[1].

IC50 & Target[1]

JAK1

<500 nM (IC50)

JAK2

500-1000 nM (IC50)

JAK3

>5000 nM (IC50)

分子量

442.51

Formula

C22H23FN4O3S

CAS 号

1973485-18-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (282.48 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2598 mL 11.2992 mL 22.5984 mL
5 mM 0.4520 mL 2.2598 mL 4.5197 mL
10 mM 0.2260 mL 1.1299 mL 2.2598 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.70 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.70 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.70 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.70 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.70 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.70 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Jin Li, et al. Composés d’imidazo[1,2-a]pyridin-2-ylamine substitués, compositions pharmaceutiques et leurs méthodes d’utilisation. Patent WO2016119700A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Itacitinib(Synonyms: INCB039110)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Itacitinib (Synonyms: INCB039110) 纯度: 99.97%

Itacitinib (INCB039110) 是一种有效的,选择性的 JAK1 抑制剂,对 人 JAK1IC50 值为 2 nM。Itacitinib 对 JAK1 选择性是 JAK2 的 20 多倍,是 JAK3 和 TYK2 的 100 多倍。

Itacitinib(Synonyms: INCB039110)

Itacitinib Chemical Structure

CAS No. : 1334298-90-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥2009 In-stock
5 mg ¥1650 In-stock
10 mg ¥2850 In-stock
50 mg ¥9950 In-stock
100 mg 询价
200 mg 询价

* Please select Quantity before adding items.

Itacitinib 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Orally Active Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Targeted Diversity Library
  • Anti-Liver Cancer Compound Library
  • Rare Diseases Drug Library

生物活性

Itacitinib (INCB039110) is an orally active and selective inhibitor of JAK1 with an IC50 of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis[1][2].

IC50 & Target[1]

JAK1

 

体外研究
(In Vitro)

Itacitinib (INCB039110) is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2. Itacitinib is used in the research of myelofibrosis[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

553.51

Formula

C26H23F4N9O

CAS 号

1334298-90-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 30 mg/mL (54.20 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8067 mL 9.0333 mL 18.0665 mL
5 mM 0.3613 mL 1.8067 mL 3.6133 mL
10 mM 0.1807 mL 0.9033 mL 1.8067 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.52 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.52 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.52 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.52 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.52 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.52 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Mascarenhas JO, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017 Feb;102(2):327-335.

    [2]. Alain Lescoat, et al. Combined Anti-Fibrotic and Anti-Inflammatory Properties of JAK-inhibitors on Macrophages in Vitro and in Vivo: Perspectives for Scleroderma-Associated Interstitial Lung Disease. Biochem Pharmacol. 2020 Jun 17;114103.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK1/TYK2-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK1/TYK2-IN-1 

JAK1/TYK2-IN-1 是一种 TYK2JAK1 的双重抑制剂(IC50 = 29 和 41 nM)。

JAK1/TYK2-IN-1

JAK1/TYK2-IN-1 Chemical Structure

CAS No. : 1883300-48-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 (IC50 = 29 and 41 nM respectively).

分子量

407.39

Formula

C18H20F3N7O

CAS 号

1883300-48-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Fensome A, et al. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. Bioorg Med Chem. 2020 May 15;28(10):115481.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK2-IN-4

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK2-IN-4 

JAK2-IN-4 (compound 16h) 是选择性的JAK2/JAK3 的抑制剂,其对JAK2 和JAK3 的IC50 值分别为 0.7 nM 和 23.2 nM。

JAK2-IN-4

JAK2-IN-4 Chemical Structure

CAS No. : 1438284-00-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively[1].

IC50 & Target

IC50: 0.7 nM/23.2 nM (JAK2/JAK3)[1].

分子量

469.56

Formula

C23H27N5O4S

CAS 号

1438284-00-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Wang Y, et al. Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors. Bioorg Med Chem. 2017 Jan 1;25(1):75-83.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK/HDAC-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK/HDAC-IN-1  纯度: 98.04%

JAK/HDAC-IN-1 是一种有效的 JAK2/HDAC 双重抑制剂,在一些血液学细胞系中具有抗增殖和促凋亡作用。JAK/HDAC-IN-1 对 JAK2 和 HDAC 的 IC50 值分别为 4 和 2 nM。

JAK/HDAC-IN-1

JAK/HDAC-IN-1 Chemical Structure

CAS No. : 2284621-75-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥1650 In-stock
5 mg ¥1500 In-stock
10 mg ¥2500 In-stock
50 mg ¥7500 In-stock
100 mg ¥12000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

JAK/HDAC-IN-1 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Histone Modification Research Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Liver Cancer Compound Library

生物活性

JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively[1].

IC50 & Target[1]

JAK2

4 nM (IC50)

JAK1

4.8 nM (IC50)

JAK3

7.4 nM (IC50)

Tyk2

49 nM (IC50)

HDAC

2 nM (IC50)

HDAC2

14 nM (IC50)

HDAC6

120 nM (IC50)

HDAC8

2470 nM (IC50)

体外研究
(In Vitro)

JAK/HDAC-IN-1 (Compound 8m) exhibits IC50s of 4.8, 7.4 and 49 nM for JAK1, JAK3 and TYK2, and 14, 120, 2470 nM for HDAC2, HDAC6 and HDAC8, respectively[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

450.32

Formula

C19H21Cl2N7O2

CAS 号

2284621-75-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : 20.83 mg/mL (46.26 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2206 mL 11.1032 mL 22.2064 mL
5 mM 0.4441 mL 2.2206 mL 4.4413 mL
10 mM 0.2221 mL 1.1103 mL 2.2206 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.62 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.62 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.62 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.62 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.62 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.62 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Liang X, et al. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. J Med Chem. 2019 Apr 25;62(8):3898-3923.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

大称量电子精密天平JA12K-1/JA16K-1/JA25K-1/JA30K-1/JA50K-5

【简单介绍】

大称量电子精密天平JA12K-1/JA16K-1/JA25K-1/JA30K-1/JA50K-5 美国进口组装,陶瓷可变电容传感器技术,超大LCD显示(带背光),内置RS232接口。

【详细说明】

 

大称量电子精密天平JA12K-1/JA16K-1/JA25K-1/JA30K-1/JA50K-5
                                 
产品名称:大称量电子精密天平
产品型号JA12K-1JA16K-1JA25K-1JA30K-1JA50K-5
产品特点
美国进口组装
陶瓷可变电容传感器技术
超大LCD显示(带背光)
内置RS232接口
产品功能
超过载
冲击保护功能
重量检测(上下限称重)
计数、百分比称重功能
克、盎司、克拉等单位转换
详细参数:
 型号
JA12K-1
JA16K-1
JA25K-1
JA30K-1
JA50K-5
称量范围(g)
12000
16000
25000
30000
50000
可读性(g)
0.1
0.1
0.1
0.1
0.5
重复性(≤g)
±0.1
±0.1
±0.1
±0.1
±0.5
线性(≤g)
±0.2
±0.2
±0.2
±0.2
±1
秤盘尺寸(mm)
275×327
 
外形尺寸325*370*125(mm)
 
 
 
金畔生物科技  专业提供

JAK2-IN-7

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK2-IN-7  纯度: 99.42%

JAK2-IN-7 是一种选择性 JAK2 抑制剂,对 JAK2,SET-2 和 Ba/F3V617F 细胞的 IC50 为 3、11.7 和 41 nM。 JAK2-IN-7 的选择性是 JAK1, JAK3,FLT3 的 14 倍以上。JAK2-IN-7 刺激细胞周期停滞在 G0/G1 期,并诱导肿瘤细胞凋亡 (apoptosis)。抗肿瘤活性。

JAK2-IN-7

JAK2-IN-7 Chemical Structure

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥4550 In-stock
5 mg ¥4500 In-stock
10 mg ¥8000 In-stock
25 mg ¥16500 In-stock
50 mg ¥25500 In-stock
100 mg ¥38000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

JAK2-IN-7 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Orally Active Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Liver Cancer Compound Library

生物活性

JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities[1].

IC50 & Target[1]

JAK1

42 nM (IC50)

JAK2

3 nM (IC50)

JAK3

94 nM (IC50)

Tyk2

75 nM (IC50)

FLT3

62 nM (IC50)

体外研究
(In Vitro)

JAK2-IN-7 (compound 13ac) (0-1000 nM; 2 hours) inhibits JAK2 and STAT5 phosphorylation in a dose-dependent manner in SET-2 and Ba/F3-JAK2V617F cells[1].
JAK2-IN-7 (10-160 nM; 24 hours) induces cell arrest in the G0/G1 phase[1].
JAK2-IN-7 (0.05-1.6 μM; 2 hours) induces apoptosis in SET-2 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line: SET-2 cells
Concentration: 10-160 nM
Incubation Time: 24 hours
Result: Induced cell arrest in the G0/G1 phase in a concentration-dependent manner.

Apoptosis Analysis[1]

Cell Line: SET-2 cells
Concentration: 0.05-1.6 μM
Incubation Time: 2 hours
Result: Induced apoptosis in SET-2 cells.

体内研究
(In Vivo)

JAK2-IN-7 (15-60 mg/kg; p.o.; daily for 16 days) shows potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model[1].
JAK2-IN-7 (30-60 mg/kg; p.o.; q.d. for 16 day) significantly ameliorates the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SET-2 cell-inoculated xenograft NOD/SCID mouse model[1]
Dosage: 15, 30, and 60 mg/kg
Administration: Orally daily for 16 days
Result: Exhibited a significant tumor growth inhibition of 82.3% without obvious weight change.

分子量

459.59

Formula

C26H33N7O

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 250 mg/mL (543.96 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1759 mL 10.8793 mL 21.7585 mL
5 mM 0.4352 mL 2.1759 mL 4.3517 mL
10 mM 0.2176 mL 1.0879 mL 2.1759 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.53 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.53 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.53 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.53 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.53 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.53 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Yang T, et al. N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms [published online ahead of print, 2020 Nov 30]. J Med Chem. 2020;10.1021/acs.jmedchem.0c01488.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK2/FLT3-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK2/FLT3-IN-1 

JAK2/FLT3-IN-1 是一种口服有效的双重 JAK2/FLT3 抑制剂,对 JAK2,FLT3,JAK1 和 JAK3 的 IC50 分别为 0.7 nM,4 nM,26 nM 和 39 nM。JAK2/FLT3-IN-1 具有抗癌活性。

JAK2/FLT3-IN-1

JAK2/FLT3-IN-1 Chemical Structure

CAS No. : 2387765-27-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

JAK2/FLT3-IN-1 的其他形式现货产品:

JAK2/FLT3-IN-1 TFA

生物活性

JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity[1].

IC50 & Target[1]

JAK2

0.7 nM (IC50)

FLT3

4 nM (IC50)

JAK1

26 nM (IC50)

JAK3

39 nM (IC50)

体外研究
(In Vitro)

JAK2/FLT3-IN-1 (0.008-1 μM; for 2 hours) down-regulates p-FLT3 in a dose-dependent manner[1].
JAK2/FLT3-IN-1 (5-100 nM; for 2 hours) has a dose-dependent effect on the induction of apoptosis in the MV4-11 cells[1].
JAK2/FLT3-IN-1 (5-100 nM; for 2 hours) strongly induces cell cycle arrest with a G1/G0 percentage of 85% at 100 nM in the MV4-11 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: MV4-11 and SET-2 cells
Concentration: 0.008, 0.04, 0.2, 1 μM
Incubation Time: For 2 hours
Result: Down-regulated p-FLT3 in a dose-dependent manner from 0.008 to 1 μM.

Apoptosis Analysis[1]

Cell Line: MV4-11 cells
Concentration: 5, 10, 50, 100 nM
Incubation Time: For 2 hours
Result: Had a dose-dependent effect on the induction of apoptosis in the MV4-11 cells.

Cell Cycle Analysis[1]

Cell Line: MV4-11 cells
Concentration: 5, 10, 50, 100 nM
Incubation Time: For 2 hours
Result: Induced cell cycle arrest with a G1/G0 percentage of 85% at 100 nM.

体内研究
(In Vivo)

JAK2/FLT3-IN-1 (30 and 60 mg/kg/day; p.o.; for 14 days) exhibits significant antitumor effects[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD/SCID mouse models[1]
Dosage: 30 and 60 mg/kg
Administration: Oral administration; daily; for 14 days
Result: Exhibited significant antitumor effects.
The tumor growth inhibitory rates (TGI) were respective 58% and 93% in the MV4-11-bearing mice model.

分子量

467.58

Formula

C25H34FN7O

CAS 号

2387765-27-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

溶解性数据
In Vitro: 

DMSO : 20.83 mg/mL (44.55 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1387 mL 10.6934 mL 21.3867 mL
5 mM 0.4277 mL 2.1387 mL 4.2773 mL
10 mM 0.2139 mL 1.0693 mL 2.1387 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 2.08 mg/mL (4.45 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (4.45 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.45 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.45 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Yang T, et al. Discovery of Potent and Orally Effective Dual JAK2/FLT3 Inhibitors for the Treatment of AcuteMyelogenous Leukemia and Myeloproliferative Neoplasms. J Med Chem. 2019 Oct 31.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

JAK2/FLT3-IN-1 TFA

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

JAK2/FLT3-IN-1 TFA  纯度: 98.94%

JAK2/FLT3-IN-1 (TFA) 是一种口服有效的双重 JAK2/FLT3 抑制剂,对 JAK2,FLT3,JAK1 和 JAK3 的 IC50 分别为 0.7 nM,4 nM,26 nM 和 39 nM。JAK2/FLT3-IN-1 (TFA) 具有抗癌活性。

JAK2/FLT3-IN-1 TFA

JAK2/FLT3-IN-1 TFA Chemical Structure

规格 价格 是否有货 数量
5 mg ¥7500 In-stock
10 mg ¥12500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

JAK2/FLT3-IN-1 TFA 相关产品

相关化合物库:

  • Bioactive Compound Library Plus

生物活性

JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity[1].

IC50 & Target

JAK1

26 nM (IC50)

JAK2

0.7 nM (IC50)

JAK3

39 nM (IC50)

FLT3

4 nM (IC50)

体外研究
(In Vitro)

JAK2/FLT3-IN-1 (0.008-1 μM; for 2 hours) (TFA) down-regulates p-FLT3 in a dose-dependent manner[1].
JAK2/FLT3-IN-1 (5-100 nM; for 2 hours) (TFA) has a dose-dependent effect on the induction of apoptosis in the MV4-11 cells[1].
JAK2/FLT3-IN-1 (5-100 nM; for 2 hours) (TFA) strongly induces cell cycle arrest with a G1/G0 percentage of 85% at 100 nM in the MV4-11 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: MV4-11 and SET-2 cells
Concentration: 0.008, 0.04, 0.2, 1 μM
Incubation Time: For 2 hours
Result: Down-regulated p-FLT3 in a dose-dependent manner from 0.008 to 1 μM.

Apoptosis Analysis[1]

Cell Line: MV4-11 cells
Concentration: 5, 10, 50, 100 nM
Incubation Time: For 2 hours
Result: Had a dose-dependent effect on the induction of apoptosis in the MV4-11 cells.

Cell Cycle Analysis[1]

Cell Line: MV4-11 cells
Concentration: 5, 10, 50, 100 nM
Incubation Time: For 2 hours
Result: Induced cell cycle arrest with a G1/G0 percentage of 85% at 100 nM.

体内研究
(In Vivo)

JAK2/FLT3-IN-1 (30 and 60 mg/kg/day; p.o.; for 14 days) (TFA) exhibits significant antitumor effects[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD/SCID mouse models[1]
Dosage: 30 and 60 mg/kg
Administration: Oral administration; daily; for 14 days
Result: Exhibited significant antitumor effects.
The tumor growth inhibitory rates (TGI) were respective 58% and 93% in the MV4-11-bearing mice model.

分子量

581.61

Formula

C27H35F4N7O3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献
  • [1]. Yang T, et al. Discovery of Potent and Orally Effective Dual JAK2/FLT3 Inhibitors for the Treatment of AcuteMyelogenous Leukemia and Myeloproliferative Neoplasms. J Med Chem. 2019 Oct 31.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

CHZ868

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

CHZ868  纯度: 99.22%

CHZ868是类型II的JAK2抑制剂,抑制EPOR JAK2 WT Ba/F3 cell细胞的IC50值为0.17 μM。

CHZ868

CHZ868 Chemical Structure

CAS No. : 1895895-38-1

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥1351 In-stock
2 mg ¥990 In-stock
5 mg ¥1450 In-stock
10 mg ¥2400 In-stock
25 mg ¥4100 In-stock
50 mg ¥7300 In-stock
100 mg ¥13000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

CHZ868 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Liver Cancer Compound Library

生物活性

CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

IC50 & Target[2]

JAK2

110 nM (IC50)

体外研究
(In Vitro)

CHZ868 potently inhibits constitutive JAK2 and STAT5 phosphorylation in JAK2V617F SET2 cells. CHZ868 potently inhibits the proliferation of SET2 cells (GI50=59nM), and has 6-fold less growth inhibitory activity against CMK cells (GI50=378nM)[1]. At 100 nM CHZ868 has activity against 26 kinases, including JAK2 and TYK2. CHZ868 is thought to engage with the hinge region of JAK2 through two H-bonds, formed between the amino-pyridine of CHZ868 and the backbone-NH/CO of L932, while the pyridine is occupying the adenine pocket of the ATP binding site. CHZ868 potently suppresses the growth of CRLF2-rearranged human B-ALL cells, abrogates JAK2 signaling[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

CHZ868 is characterized by high passive permeability, good metabolic stability, and low water solubility, as well as by moderate blood clearance and good oral bioavailability, making it suitable for in vivo use. CHZ868 improves survival in mice with human or murine B-ALL. CHZ868 and dexamethasone synergistically induces apoptosis in JAK2-dependent B-ALLs and further improves survival compared to CHZ868 alone[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

423.42

Formula

C22H19F2N5O2

CAS 号

1895895-38-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (236.17 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3617 mL 11.8086 mL 23.6172 mL
5 mM 0.4723 mL 2.3617 mL 4.7234 mL
10 mM 0.2362 mL 1.1809 mL 2.3617 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.90 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.90 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.90 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Meyer SC, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2015 Jul 13;28(1):15-28.

    [2]. Wu SC, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13;28(1):29-41.

Cell Assay
[2]

CHZ868 is dissolved in DMSO to make 10 mM stock solution and diluted in culture media. Cells are treated with CHZ868 (0, 0.05, 0.1, 0.2 μM) or vehicle (DMSO). After 48 hr (Ba/F3 cells) or 72 hr (MHH-CALL4 and PDX cells), CellTiter-Glo Luminescent Cell Viability Assay is added (10 μL undiluted or 25 μL of a 1:2 dilution in each well) and plates are read[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Mice: CHZ868 is reconstituted in 0.5% methylcellulose / 0.5% Tween-80 and administered at doses of 10 or 30 mg/kg/day by oral gavage. Pharmacokinetic/pharmacodynamic and efficacy studies in the mouse model of rhEpo-induced polycythemia are carried out essentially as reported. Detection of STAT5 phosphorylation in spleen lysates by Meso Scale Discovery is performed[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Meyer SC, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2015 Jul 13;28(1):15-28.

    [2]. Wu SC, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13;28(1):29-41.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

SC99

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

SC99  纯度: 99.07%

SC99 是口服有效的,选择性的 STAT3 抑制剂,靶向 JAK2-STAT3 途径。SC99 结合在 JAK2 的 ATP 结合袋中。SC99 抑制 JAK2 和 STAT3 的磷酸化,而对与 STAT3 信号相关的其他激酶没有影响。SC99 抑制血小板活化、聚集,并显示有效的抗骨髓瘤,抗血栓形成活性。

SC99

SC99 Chemical Structure

CAS No. : 882290-02-0

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥2750 In-stock
5 mg ¥2500 In-stock
10 mg ¥4000 In-stock
50 mg ¥11500 In-stock
100 mg ¥17500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SC99 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Small Molecule Immuno-Oncology Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Orally Active Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library

生物活性

SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities[1][2][3].

IC50 & Target

STAT3

 

JAK2

 

体外研究
(In Vitro)

SC99 (10 or 30 μM; for 72 hours) induces MM cell death[1].
SC99 (10 μM; 24 hours) decreases the p-STAT3 level but has no effects on total STAT3 expression. SC99 (2.5, 5, 10, 20 μM; for 60 mins) inhibits JAK2 phosphorylation in a concentration-dependent manner but does not inhibit the phosphorylation levels of AKT, ERK, mTOR or c-Src at a concentration up to 20 μM[1].
SC99 (1.25, 2.5, 5 μM; pre-treated for 10 min) inhibits collagen (2 μg/mL) and thrombin (0.02 U/mL) induced phosphorylation of STAT3 in a concentration-dependent manner[2].
SC99 (pre-treated for 2 hours) inhibits IL-6 (50 ng/ml; for 20 min) induced STAT3 nuclear translocation in OPM2 cells[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line: Six multiple myeloma (MM) cell lines (LP1, JJN3, RPMI-8226, U266, OPM2 and OCI-MY5)
Concentration: 10 or 30 μM
Incubation Time: For 72 hours
Result: Induced MM cell death.

Apoptosis Analysis[1]

Cell Line: MM cell lines[1]
Concentration: 10 μM
Incubation Time: 24 hours
Result: Decreased the p-STAT3 level but had no effects on total STAT3 expression in all cell lines examined.

体内研究
(In Vivo)

SC99 (30 mg/kg; orally; daily; for continuous 14 or 28 days) delays myeloma tumor growth in xenograft mice models[1].
SC99 (5, 10, 15 mM, 15 μL; ICV) produces an effective inhibitory effect on the phosphorylation of JAK2 and STAT3 in middle cerebral artery occlusion and reperfusion (MCAO/R) model (adult male SD rats; 250-300 g). SC99 ameliorates neuronal apoptosis and degeneration, neurobehavioral deficits, inflammatory response and brain edema[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nude mice with Human MM cells OPM2 or JJN3[1]
Dosage: 30 mg/kg
Administration: Orally; daily; for continuous 14 or 28 days
Result: Delayed myeloma tumor growth in xenograft mice models and suppressed tumor growth more than 40% in 14 days in the OPM2 model.

分子量

336.15

Formula

C15H8Cl2FN3O

CAS 号

882290-02-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 83.33 mg/mL (247.90 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.9749 mL 14.8743 mL 29.7486 mL
5 mM 0.5950 mL 2.9749 mL 5.9497 mL
10 mM 0.2975 mL 1.4874 mL 2.9749 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 2.08 mg/mL (6.19 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (6.19 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (6.19 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (6.19 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Zubin Zhang, et al. A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway. Oncotarget. 2016 Feb 23;7(8):9296-308.

    [2]. Zhuan Xu, et at. A novel STAT3 inhibitor negatively modulates platelet activation and aggregation. Acta Pharmacol Sin. 2017 May;38(5):651-659.

    [3]. Yiping Ding, et al. Effects of SC99 on cerebral ischemia-perfusion injury in rats: Selective modulation of microglia polarization to M2 phenotype via inhibiting JAK2-STAT3 pathway. Neurosci Res. 2019 May;142:58-68.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

上海恒平电子天平JA50K-5

上海恒平电子天平JA50K-5

  • 品牌 恒平|SDPTOP
  • 型号 JA50K-5
  • 商品详情

    特点 

    美国进口组装   专利陶瓷可变电容传感器技术   超大LCD显示(带背光)   内置RS232接口

     

    功能

    超过载、冲击保护功能   重量检测(上下限称重)   计数、百分比称重功能
    克、盎司、克拉等单位转换



    JA12K-1

    JA16K-1

    JA25K-1

    JA30K-1

    JA50K-5

    称量范围(g)

    12000

    16000

    25000

    30000

    50000

    可读性(g)

    0.1

    0.1

    0.1

    0.1

    0.5

    重复性(≤g)

    ±0.1

    ±0.1

    ±0.1

    ±0.1

    ±0.5

    线性(≤g)

    ±0.2

    ±0.2

    ±0.2

    ±0.2

    ±1

    秤盘尺寸(mm)

    275×327


    外形尺寸325*370*125(mm)


  • 上海恒平电子天平JA30K-1

    上海恒平电子天平JA30K-1

  • 品牌 恒平|SDPTOP
  • 型号 JA30K-1
  • 商品详情

    特点 

    美国进口组装   专利陶瓷可变电容传感器技术   超大LCD显示(带背光)   内置RS232接口

     

    功能

    超过载、冲击保护功能   重量检测(上下限称重)   计数、百分比称重功能
    克、盎司、克拉等单位转换

     

    JA12K-1

    JA16K-1

    JA25K-1

    JA30K-1

    JA50K-5

    称量范围(g)

    12000

    16000

    25000

    30000

    50000

    可读性(g)

    0.1

    0.1

    0.1

    0.1

    0.5

    重复性(≤g)

    ±0.1

    ±0.1

    ±0.1

    ±0.1

    ±0.5

    线性(≤g)

    ±0.2

    ±0.2

    ±0.2

    ±0.2

    ±1

    秤盘尺寸(mm)

    275×327

     

    外形尺寸325*370*125(mm)

  • 上海恒平电子天平JA25K-1

    上海恒平电子天平JA25K-1

  • 品牌 恒平|SDPTOP
  • 型号 JA25K-1
  • 商品详情

    特点 

    美国进口组装   专利陶瓷可变电容传感器技术   超大LCD显示(带背光)   内置RS232接口

     

    功能

    超过载、冲击保护功能   重量检测(上下限称重)   计数、百分比称重功能
    克、盎司、克拉等单位转换

     

    JA12K-1

    JA16K-1

    JA25K-1

    JA30K-1

    JA50K-5

    称量范围(g)

    12000

    16000

    25000

    30000

    50000

    可读性(g)

    0.1

    0.1

    0.1

    0.1

    0.5

    重复性(≤g)

    ±0.1

    ±0.1

    ±0.1

    ±0.1

    ±0.5

    线性(≤g)

    ±0.2

    ±0.2

    ±0.2

    ±0.2

    ±1

    秤盘尺寸(mm)

    275×327

     

    外形尺寸325*370*125(mm)